Features of laboratory markers in pregnant women with antiphospholipid syndrome and retrochorial hematoma by Tomniuk, Oleh
Original Research Article:
full paper




FEATURES OF LABORATORY MARKERS IN PREGNANT 
WOMEN WITH ANTIPHOSPHOLIPID SYNDROME 
AND RETROCHORIAL HEMATOMA
Oleh Tomniuk
Department of Obstetrics, Gynecology and Perinatology
Ukrainian State Institute of Reproductology
Shupyk National Healthcare University of Ukraine
9 Dorohozhytska str., Kyiv, Ukraine, 04112
tomnuk_oleg@ukr.net
Abstract
The aim. Study of hemostasis, antiphospholipid antibody levels and immunological parameters in pregnant women with 
antiphospholipid syndrome (APS), in particular with retrochorial hematoma (RCH).
Materials and methods. 90 women were selected and divided into two groups: the control group – 30 pregnant women with 
a normal pregnancy (without APS) and the main group – 60 pregnant women with APS. Women in the main group were diagnosed 
with APS before pregnancy. In turn, the main group was divided into two subgroups: 1 subgroup – 41 pregnant women without RCH 
and 2 subgroup – 19 pregnant women with RCH.
The main indicators of hemostasis were determined in all pregnant women, namely: the degree and rate of platelet aggre-
gation, Willebrand factor, D-dimers. In addition, the level of antiphospholipid antibodies (APLA), antibodies to β2-glycoprotein, to 
annexin V, to prothrombin was examined, and the level of annexin V was also determined. The absolute and relative content of Treg, 
CD3+, T-lymphocytes, CD4+ (T-helpers), CD8+ (cytotoxic T-lymphocytes), CD19+ (B-lymphocytes), CD16+CD56+ (NK cells), 
CD16+CD56+CD107a+ (activated NK cells). 
Results. The obtained results showed that in pregnant women with APS compared to pregnant women without APS there are 
statistically significantly higher values of the degree and rate of platelet aggregation (90.6 ± 6.3 % and 106.3 ± 6.7 % vs. 65.3 ± 5.3 % 
and 73.4 ± 5.6 %, respectively). There were also higher values of Willebrand factor and D-dimers (2.5 ± 0.3 IU/ml and 378.1 ± 34.3 ng/
ml against 1.7 ± 0.2 IU/ml and 268.1 ± 27, 3 ng/ml, respectively).
APLAs were significantly higher in pregnant women with APS compared with pregnant women in the control group, namely: 
16.1 ± 1.5 vs. 3.8 ± 0.4 U/ml. With regard to antibodies to β2-glycoprotein, to annexin V, to prothrombin and to the level of annexin V, 
their values were also statistically significantly higher in the group of pregnant women with APS.
In addition, the results of the study showed that pregnant women with APS showed changes in subpopulations of immuno-
competent cells.
However, examining the difference in hemostasis, antibody content, and level of lymphocyte subpopulations between preg-
nant women with APS with and without RCH, it was found that their shifts in pregnant women with RCH were more pronounced 
than in women without RCH. 
Conclusions. Pregnant women with APS are characterized by significantly more significant changes in hemostasis, mani-
fested by activation of intravascular thrombosis. In addition, such pregnant women had a significantly higher concentration of auto-
antibodies. There are also changes in the immune system, in particular, a decrease in Treg-cells, which have the ability to reduce the 
specific proliferation and effector functions of lymphocytes, thereby participating in the pathogenesis of APS. 
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1. Introduction
Despite significant advances in medicine, the problem of miscarriage still remains one of 
the most difficult. Cases of miscarriage cause both a negative psycho-emotional reaction in pa-
rents and pathology in a woman’s physical health, so the doctor’s task is to determine the causes 
of failure and conduct sound pre-pregnancy training, maximally contributing to the normal course 
of subsequent pregnancy. One of the causes of miscarriage is antiphospholipid syndrome, which 
is an autoimmune process in which antibodies are formed to phospholipids of platelet membranes, 
endothelial cells, cells of the nervous system. As a result of such processes, blood clots appear in the 
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vessels, which is accompanied by further complications during pregnancy. The most common such 
complications include retrochorial hematoma, which is a blood clot formed as a result of violation 
of the integrity of the walls of blood vessels and blood flow between the chorion and the uterine 
wall. Such hematomas are often accompanied by the development of placental dysfunction and 
fetal growth retardation [1, 2].
The cause of thrombosis in APS is not a direct effect of APLA on negatively charged or 
neutral phospholipids, and in most cases it is indirect, i.e. protein-mediated. Such a cofactor protein 
is more often plasma protein β2-glycoprotein-1, which, when bound to phospholipids, forms a true 
antigen for APLA [3, 4]. Other cofactor proteins include prothrombin, macromolecular kininogen, 
annexin, proteins C and S, and others [5, 6].
In addition, natural T-cell regulators (Treg) play an important role in the induction of tole-
rance to fetal alloantigens. It is believed that Treg-cells can inhibit the cytotoxic activity of CD8+ 
T lymphocytes and NK cells. Therefore, Treg-cells are considered as the main contenders for the 
role of cells that control the immune balance in the «mother-fetus» system, and they are involved in 
the pathogenesis of APS during pregnancy. Given that the normal course of pregnancy is the key to 
normal fetal development, the study of laboratory parameters in pregnant women with APS, espe-
cially with RCH, in order to further develop improved tactics of pregnancy remains relevant [7, 8].
The aim is to study the features of hemostasis, the level of antiphospholipid antibodies and 
immunological parameters in pregnant women with antiphospholipid syndrome, in particular with 
retrochorial hematoma.
2. Materials and methods
The study was conducted from 2017 to 2020 on the basis of the Department of Obstet-
rics, Gynecology and Perinatology of the Shupyk National Healthcare University of Ukraine on 
the basis of the Kyiv Maternity Hospital No. 1 (gynecological department). To achieve this goal, 
90 women were selected and divided into two groups: the control group – 30 pregnant women with 
a normal pregnancy (without APS) and the main group – 60 pregnant women with APS. Women in 
the main group were diagnosed with APS before pregnancy. In turn, the main group was divided 
into two subgroups: 1st subgroup – 41 pregnant women without RCH and 2nd subgroup – 19 preg-
nant women with RCH.
The study was conducted in accordance with the Declaration of Helsinki according to 
the conclusion of the Commission on Ethics of the Shupyk National Healthcare University of 
Ukraine (minutes No. 2 from 09.02.2017). Informed consent to participate in the study was ob-
tained from all women.
All pregnant women were included in the study at 5–7 weeks of gestation, which were exami-
ned and analyzed. The age of the studied pregnant women ranged from 21 to 38 years. The average 
age of women in the control group – 29.7 ± 3.3 years, the main group – 29.4 ± 2.9 years (p > 0.05).
According to the obstetric and gynecological history, the results of detection of gynecolo-
gical and somatic diseases and examination for the presence of chronic extragenital infection, the 
selected groups of pregnant women were identical, no significant differences were found.
Criteria for inclusion were: reproductive age of women, I trimester of pregnancy, the pre-
sence of a history of miscarriage, confirmed by APS for the main group.
The main indicators of hemostasis were determined for all pregnant women in the study 
groups, namely: the degree and rate of platelet aggregation («Platelet Aggregation Kit», «Helena 
biosciences Europe», UK), Willebrand factor (test system Willebrand factor antigen, Helena bio-
sciences Europe, UK), D-dimers (Cobas 6000, Roche Diagnostics (Switzerland)). 
In addition, the level of APLA (anticardiolipin antibodies), antibodies to β2-glycoprotein, 
annexin V, prothrombin was examined, and the level of annexin V was determined. Antibodies 
were determined by enzyme-linked immunosorbent assay using the «ORGenTec kit» (Germany).
The absolute and relative content of Treg, CD3+, T-lymphocytes (antibody conjugates, 
Beckman Coulter, USA) were also determined; CD4+ (T-helpers), CD8+ (cytotoxic T-lympho-
cytes), CD19+ (B-lymphocytes), CD16+CD56+ (NK cells), CD16+CD56+CD107a+ (activated 
NK cells). Studies of immunological subpopulations were performed using two-color flow laser 
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cytometry using monoclonal antibodies (Caltag laboratories, USA). All pregnant women were 
compared according to the results of the studied indicators.
Statistica and Microsoft Office Excel were used for statistical processing of the obtained re-
sults. Evaluation of the statistical significance of the obtained data was performed using Student’s 
t-test. The differences were considered statistically significant at p < 0.05.
3. Results
The study compared laboratory parameters of pregnant women with APS and pregnant 
women of the control group, i.e. with physiological pregnancy without APS, in the first trimester 
of pregnancy. It was found that for most of the compared parameters of hemostasis (the degree and 
rate of platelet aggregation, the level of D-dimers) in pregnant women with APS, their values were 
significantly higher than in women from the control group (Table 1).
Table 1
Indicators of the hemostasis system of the examined pregnant women in the first trimester of pregnancy
Indicators Control group n = 30
Main group (pregnant with APS)
n = 60
The degree of platelet aggregation, % 65.3 ± 5.3 90.6 ± 6.3*
The rate of platelet aggregation, %/min 73.4 ± 5.6 106.3 ± 6.7*
Willebrand factor, IU/ml 1.7 ± 0.2 2.5 ± 0.3*
D-dimers, ng/ml 268.1 ± 27.3 378.1 ± 34.3*
Note: * – significant differences (p < 0.05) relative to the control group
The results showed that pregnant women with APS have a more pronounced activation of 
the hemostasis system than in physiological pregnancy. This is confirmed by the obtained data 
on the degree and rate of platelet aggregation, the values of which were above normal in preg-
nant women with APS. Other studied indicators of hemostasis (Willebrand factor and D-dimers), 
although significantly higher in the main group, but did not exceed the norm.
Studies have shown that the concentrations of autoantibodies in pregnant women with APS 
were significantly (p < 0.05) higher than in women with physiological pregnancy (Table 2).
Table 2
Levels of autoantibodies in the examined pregnant women in the first trimester of pregnancy
Indicators Control group n = 30
Main group (pregnant with APS)
n = 60
APLA, U/ml 3.8 ± 0.4 16.1 ± 1.5*
Antibodies to β2-glycoprotein, U/ml 3.1 ± 1.5 30.2 ± 4.3*
Antibodies to annexin V, U/ml 1.9 ± 0.2 4.2 ± 0.4*
Antibodies to prothrombin, U/ml 4.9 ± 0.5 8.8 ± 0.8*
Annexin V, ng/ml 1.1 ± 0.2 2.1 ± 0.3*
Note: * – significant differences (p < 0.05) relative to the control group
Analysis of the obtained immunological parameters showed that the values of the relative 
and absolute content of Treg in the blood of pregnant women with APS were significantly (p < 0.05) 
lower than in patients of the control group (Table 3). 
It was also found that the level of CD3+ and CD4+ T-lymphocytes in the blood in both 
groups did not differ significantly. In addition, there was a slight decrease in the absolute number of 
T-helpers in pregnant women with APS – 0.9 ± 0.09×103/μl, in contrast to women with physiological 
pregnancy, where this figure was 0.8 ± 0.08×103/μl.
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Immunological parameters of the examined pregnant women (M ± m)
Indicators Control group n = 30
Main group
n = 60
Treg, % CD3+CD4+CD127 (low/–) 6.9 ± 0.9 3.8 ± 0.5*
Treg, abs.(×103)/μl CD3+CD4+CD127 (low/–) 0.112 ± 0.001 0.063 ± 0.006*
CD3+, % T-lymphocytes 75.2 ± 6.2 74.2 ± 7.4
CD3+, abs./(×103)/μl 1.3 ± 0.2 1.3 ± 0.3
CD19+, % B-lymphocytes 10.8 ± 0.8 16.6 ± 1.3*
CD19+, abs. B-lymphocytes (×103)/μl 0.2 ± 0.03 0.3 ± 0.004
CD4+, % T-helpers 46.5 ± 4.5 45.5 ± 4.3
CD4+, abs. T-helpers (×103)/μl 0.9 ± 0.08 0.8 ± 0.09
CD8+, % cytotoxic T-lymphocytes 28.6 ± 1.8 34.1 ± 2.9*
CD8+, abs. cytotoxic T-lymphocytes (×103)/μl 0.5 ± 0.03 0.6 ± 0.004
CD16+CD56+, % NK-cells 8.8 ± 0.5 8.4 ± 0.8
CD16+CD56+, abs. NK-cells (×103)/μl 0.2 ± 0.02 0.18 ± 0.01*
CD16+CD56+CD107a, activated NK-cells, % 43.2 ± 4.3 23.6 ± 2.3*
Note: * – significant differences (p < 0.05) relative to the control group
In addition, there was a significant increase in the relative content of B-lymphocytes (CD19+ 
lymphocytes) compared with similar indicators in women of the control group. As for the absolute 
number of CD19+ lymphocytes, their number was also higher in the group of pregnant women with 
APS, although, however, no significant difference in the intergroup comparison was found.
Evaluation of the relative content of CD16+/CD56+ (NK-cells) showed that pregnant wo-
men with APS had a slightly lower number of cells in this subpopulation compared to the va-
lue in the group with the physiological course of pregnancy, although it was insignificant. When 
comparing the content of the absolute number of lymphocytes in the blood with the phenotype 
CD16+/CD56+ (NK-cells), it was found that in pregnant women with APS, the value of this indica-
tor was also lower, although insignificant than in women in the control group.
The obtained data on the content of activated NK-cells showed that in pregnant women 
with APS it was significantly (p < 0.05) reduced compared to pregnant women with physiological 
pregnancy.
Therefore, the obtained data of the studied laboratory parameters showed that in the group 
of pregnant women with APS in most cases there was a higher proportion compared to pregnant 
women in the control group.
In addition, given the high incidence of retrochorial hematoma in women with early APS 
in early pregnancy, which is followed by significant complications, hemostasis and immunolo-
gical parameters were also studied in such women, and compared to pregnant women with APS 
without RCH.
Thus, during the study, even more pronounced changes were found in pregnant women with 
APS with the development of RCH, compared with pregnant women with APS without RCH. As 
can be seen from Table 4, pregnant women with RCH had significantly (p < 0.05) higher values of 
the degree of aggregation of platelets and D-dimers. Aggregation rate and Willebrand factor levels 
in these patients also exceeded the corresponding values in women without RCH, although no sig-
nificant differences were observed.
After analyzing the obtained data, it was found that pregnant women with RCH had sig-
nificantly (p < 0.05) increased levels of APLA, antibodies to β2-glycoprotein, annexin V and pro-
thrombin compared with those in women with APS without RCH. The level of AT to β2-glycopro-
tein in pregnant women with RCH was more than 1.5 times higher than in patients without RCH.
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Laboratory parameters in pregnant women with and without RCH in the I trimester
Indicators





The degree of platelet aggregation, % 90.7 ± 4.1 107.5 ± 6.2*
Rate of platelet aggregation, %/min 104.4 ± 5.8 114.3 ± 9.1
Willebrand factor, IU/ml 2.7 ± 0.2 2.8 ± 0.2
D-dimers, ng/ml 352.2 ± 39.8 403.5 ± 28.4*
APLA, U/ml 17.1 ± 2.9 22.3 ± 2.1*
Antibodies to β2-glycoprotein, U/ml 38.5 ± 3.1 55.3 ± 5.1*
Antibodies to annexin V, U/ml 3.8 ± 0.4 5.7 ± 0.6*
Antibodies to prothrombin, U/ml 8.8 ± 0.8 12.7 ± 1.3*
Annexin V, ng/ml 1.9 ± 0.2 2.3 ± 0.3
Treg, % CD3+CD4+CD127 (low/–) 3.8 ± 0.3 2.5 ± 0.4*
CD3+, % T-lymphocytes 72.6 ± 5.9 70.2 ± 6.8
CD19+, % B-lymphocytes 16.2 ± 2.2 19.9 ± 1.9
CD4+, % T-helpers 46.6 ± 4.7 39.5 ± 3.9*
CD8+, % cytotoxic T-lymphocytes 33.3 ± 3.3 38.2 ± 3.4
CD16+CD56+, % NK-cells 8.6 ± 0.9 9.2 ± 0.9
CD16+CD56+CD107a, activated NK-cells, % 24.8 ± 2.5 19.5 ± 2.0
Note: * – differences are significant (p < 0.05) when compared with the group without RCH
Comparing the obtained data of immunological parameters revealed more significant devia-
tions in the group with RCH compared with the group of pregnant women with APS without RCH. 
Thus, a significantly lower (p < 0.05) lower content of Treg and CD4+ lymphocytes in pregnant 
women with RCH was found in contrast to pregnant women without RCH. At the same time, slight-
ly higher levels of CD19+/56+ and CD8+ cytotoxic lymphocytes were recorded in women with 
RCH compared to those in pregnant women with APS without RCH, but no significant differences 
were observed.
A slightly lower level of activated NK cells was also found in pregnant women with 
RCH (19.5 ± 2.0 %) compared to pregnant women without RCH (24.8 ± 2.5 %), however, no signifi-
cant intergroup differences were found.
Therefore, laboratory shifts in pregnant women with RCH were more pronounced than in 
women without RCH. At the same time, in pregnant women with RCH revealed changes in hemo-
stasis, elevated AT levels, as well as shifts in the levels of some subpopulations of lymphocytes.
4. Discussion of research results
Miscarriage and perinatal loss remain among the most pressing issues in obstetrics and 
gynecology, as they remain high worldwide. In addition, frequent fetal losses have a nega-
tive impact on both a woman’s reproductive health and her psychological health [9, 10]. APS 
is one of the causes of miscarriage and perinatal loss. It is classified as a disease such as au-
toimmune thrombophilia. APS is characterized by the formation of thrombosis of different 
localization, which leads to cardiovascular, hematological disorders and, as a result, to the usual 
fetal loss [11, 12].
According to the research, during APS the formation of autoantibodies – antiphos-
pholipid antibodies – to phospholipid determinants, which are involved in the formation of the 
cytolemma of erythrocytes, platelets, vascular endothelium. The formation of such autoanti-
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bodies leads both to their damage and to disturbances in the hemostasis system with the for-
mation of thrombosis [13, 14]. The results showed that in pregnant women with APS the values 
of all studied parameters of hemostasis – the degree and rate of platelet aggregation, the level 
of D-dimers – were significantly higher than in pregnant women of the control group: the de-
gree of platelet aggregation – 90.6 ± 6.3 % vs. 65. 3 ± 5.3 % (p < 0.05); platelet aggregation 
rate –106.3 ± 6.7% %/min against 73.4 ± 5.6% %/min (p < 0.05); the level of Willenbrand factor – 
2.5 ± 0.3 IU/ml against 1.7 ± 0.2 IU/ml (p < 0.05) and D-dimers – 378.1 ± 34.3 ng/ml against 268, 
1 ± 27.3 ng/ml (p < 0.05).
It is known that the effect of APLA on phospholipids is not direct, but mediated through 
cofactor proteins, which include β2-glycoprotein-1, prothrombin, annexin, etc. [15, 16]. The results 
of the study showed that in pregnant women with APS the concentration of APLA, antibodies 
to β2-glycoprotein, to annexin V, to prothrombin, and the level of annexin V were statistically 
significantly higher than in women from the control group, i.e. in pregnant women without APS. 
Thus, the level of APLA in pregnant women with APS was 16.1 ± 1.5 U/ml, and AT to β2-glyco-
protein – 30.2 ± 4.3 U/ml, which was significantly higher compared to the control group – 3.8 ± 0.4 
and 3.1 ± 1.5, respectively (p < 0.05). As for other studied antibodies, there was a similar pattern: 
antibodies to annexin V and prothrombin (4.2 ± 0.5 and 8.8 ± 0.8 U/ml) are significantly higher 
compared to the control group (1.9 ± 0.2 and 4.9 ± 0.5 U/ml, respectively) (p < 0.05). The concentra-
tion of annexin V was 2.1 ± 0.3 ng/ml, which was statistically significantly higher compared to the 
control group, where this figure was 1.1 ± 0.2 ng/ml (p < 0.05).
There is also a theory that the immune system plays a significant role in the development of 
APS. For example, in the induction of tolerance to fetal alloantigens involved T cells (Treg), which 
can inhibit the activity of CD8+ T lymphocytes and NK cells and participate in the development 
of APS [17, 18].
The results show that the values of the relative and absolute content of Treg in the peripheral 
blood in pregnant women with APS were significantly lower than in pregnant women in the con-
trol group (p < 0.05). Thus, the assessment of the absolute amount of Treg revealed that in women 
without APS the values were at the level of 0.112–0.001x103/μl, in pregnant women with APS the 
amount of Treg was significantly lower – 0.063 ± 0.006x103/μl (p < 0.05).
In addition, it was found that in the group of pregnant women with APS compared with the 
control group there is an increase in the absolute and relative content of CD19+ B-lymphocytes and 
CD8+ cytotoxic T-lymphocytes.
In addition, in obstetrics and gynecology, much attention is paid to the presence of RCH 
in the first trimester of pregnancy, especially in pregnant women with APS. This attention is 
due to the fact that women with RCH have a greater number of complications during pregnan-
cy, including placental dysfunction and fetal growth retardation [19, 20]. The results showed that 
in pregnant women with APS in combination with RCH there are significantly greater chang-
es in both the hemostasis system and the immune system. Thus, statistically significantly higher 
were such indicators as: the degree of platelet aggregation in the group with APS in combination 
with RCH was 107.5 ± 6.2 % against 90.7 ± 4.1 % in the group with APS without RCH (p < 0.05); 
the level of D-dimers is 403.5 ± 28.4 ng/ml against 352.2 ± 39.8 ng/ml (p < 0.05); APLA – 
22.3 ± 2.1 U/ml vs. 17.1 ± 2.9 U/ml (p < 0.05); antibodies to β2-glycoprotein – 55.3 ± 5.1 U/ml against 
38.5 ± 3.1 U/ml (p < 0.05); antibodies to annexin V – 5.7 ± 0.6 U/ml against 3.8 ± 0.4 U/ml (p < 0.05); 
antibodies to prothrombin – 12.7 ± 1.3 U/ml against 8.8 ± 0.8 U/ml (p < 0.05). Also in pregnant 
women with APS with RCH was a significant decrease in some immunological parameters com-
pared with pregnant women with APS without RCH, namely: Treg lymphocytes – 2.5 ± 0.4 % 
vs. 3.8 ± 0.3 % (p < 0.05); CD4+ T-helpers – 39.5 ± 3.9 % vs. 46.6 ± 4.7 % (p < 0.05). The obtained 
data confirm the negative effect of RCH on the state of hemostasis in women with APS. 
Study limitations. The study did not include pregnant women with somatic diseases in the 
stage of decompensation, malformations and neoplasms of the reproductive system, which had 
such factors of miscarriage as: endocrine, infectious and genetic.
Prospects for further research. Decreased incidence of miscarriage and perinatal patho-
logy in women with antiphospholipid syndrome and retrochorial hematoma.
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The results of the study showed that pregnant women with APS, in particular in the first tri-
mester of pregnancy, had significantly more significant changes in hemostasis. Thus, it was found 
that in pregnant women with APS the main indicators of hemostasis, namely: the degree and rate 
of platelet aggregation, Willebrand factor, the level of D-dimers, were significantly higher than in 
pregnant women without APS.
Also in the group of pregnant women with APS there was a significantly higher concentra-
tion of autoantibodies to APLA, to β2-glycoprotein, to annexin V, to prothrombin, as well as the 
level of annexin V compared to pregnant women in the control group. In addition, it was found that 
the values of the relative and absolute content of Treg, T-helpers, CD16+/CD56+ (NK cells), as well 
as activated NK cells in the blood of pregnant women with APS were significantly lower (p < 0.05) 
than in patients of the control group. At the same time, there was an increase in the absolute and 
relative number of CD19+ B-lymphocytes, CD8+ cytotoxic T-lymphocytes compared to pregnant 
women in the control group.
Comparing the study laboratory parameters (hemostasis, AT, lymphocyte subpopulations) 
between pregnant women with APS with and without RCH, it was found that their shifts in preg-
nant women with RCH were more pronounced than in women without RCH. 
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